The news in the past week has been the lack of deal news. The past week has been very quiet on the dealmaking front, with very little of significance in terms of deals from bigpharma or deals with a high headline value Read the full story
Tag Archive | "review"
- Amag Pharma falls after ending sale talks
- OncoMed seeks $115 million IPO
- BMS and Tsinghua University in structural biology research pact
- Menarini licenses rights to Priligy
- The trouble with tech M&A
- Top twenty partnering deals of 2011 have a combined value of over $21 billion
- The Hep C club: the new dealmakers hot spot
- Vical and Teva Pharmaceutical establish sales and marketing agreement for Allovectin-7(r) in Israel
- Biopharma partnering: Perspectives from BCG’s latest biotech and pharma partnering study
- Biotech investing at a crossroads?
- Steve Poile: HI Beverly Sure, your email address is added an...
- Beverly Cormier: This is a great report. I would to receive it via...
- Rob Grundy: Hi Bruce, Great article. 'Let me frame up tw...
- Joe Patti: Jan. 24, 2012-BioLineRx signed an “exclusive licen...
- Steve Poile: Hi Kevin Thanks for this. I believe it is alrea...
Home | Reports | Services | Insight | News | Events | Scorecard | About us | Terms & conditions | Subscribe | Contact us
© 2012 Wildwood Ventures Ltd. 